Table 2. Coefficients and Standard Errors of the Cox Prediction Model^a.

Factor	Estimated coefficient (SE)
Treatment sorafenib vs reoperative hepatectomy or thermoablation	6.59 (1.91)
Treatment chemoembolization vs reoperative hepatectomy or thermoablation	3.65 (2.03)
Female (age)	0.04 (0.02)
Cirrhosis: yes vs no	0.15 (0.29)
Female (No. of recurrence nodules): 1	−0.04 (0.65)
Female (No. of recurrence nodules): 2	7.80 (5.69)
Female (size recurrence nodules): 1	0.32 (0.17)
Female (size recurrence nodules): 2	0.85 (0.38)
Bilobar recurrence: yes vs no	0.63 (0.39)
Extrahepatic recurrence: yes vs no	1.02 (0.35)
Female (time to recurrence)	0.68 (0.24)
Sorafenib × female (age)	−0.05 (0.02)
Chemoembolization × female (age)	−0.02 (0.02)
Sorafenib × cirrhosis	−0.30 (0.37)
Chemoembolization × cirrhosis	0.31 (0.40)
Sorafenib × female (No. of recurrence nodules): 1	−1.27 (0.89)
Chemoembolization × female (No. of recurrence nodules): 1	−0.86 (0.85)
Sorafenib × female (No. of recurrence nodules): 2	−4.89 (6.51)
Chemoembolization × female (No. of recurrence nodules): 2	−5.47 (6.68)
Female (No. of recurrence nodules): 1 × female (No. of recurrence nodules): 2	−0.15 (0.13)
Sorafenib × female (size recurrence nodules): 1	0.14 (0.12)
Chemoembolization × female (size recurrence nodules): 1	−0.06 (0.17)
Sorafenib × female (size recurrence nodules): 2	0.45 (0.39)
Chemoembolization × female (size recurrence nodules): 2	0.09 (0.61)
Female (size recurrence nodules): 1 × female (size recurrence nodules): 2	0.08 (0.04)
Sorafenib × bilobar recurrence	−0.88 (0.51)
Chemoembolization × bilobar recurrence	−0.87 (0.47)
Sorafenib × extrahepatic recurrence	−0.62 (0.42)
Chemoembolization × extrahepatic recurrence	0.90 (0.57)
Sorafenib × female (time to recurrence)	−0.38 (0.31)
Chemoembolization × female (time to recurrence)	0.16 (0.33)

^a All second-order interactions of the features with treatment are included.